Gastroparesis, also known as delayed gastric emptying, can be defined
as a disease of the stomach muscles or the nerves controlling these
muscles that causes the stomach muscles to stop functioning. It
affects the spontaneous movement of the stomach muscles. Impaired
mobility of the stomach muscles leads to emptying of the stomach.
Gastroparesis occurs due to damage to the vagus nerve either because
of injury or illness. Gastroparesis that commonly occurs among people
is known as idiopathic gastroparesis, indicating that the actual
cause of the disease is unclear. Diabetes is other common cause of
gastroparesis, as high blood sugar levels leads to slow damage of the
vagus nerve causing gastroparesis. The common symptoms of the disease
include nausea, feeling of fullness, gastroesophagial reflux,
abdominal bloating, lack of appetite, and pain in the stomach area.
Request Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39305
The global gastroparesis treatment market is anticipated to record
moderate growth during the forecast period. Growth of the market can
be attributed to increase in prevalence of diabetes mellitus among
people, rise in number of surgeries being performed which could lead
to post-operative gastroparesis, introduction of novel drugs, and
focus of market players on research and development to launch
specific drugs for the treatment of gastroparesis. Additionally,
untapped opportunities in the emerging markets such as India and
China are likely to fuel the growth of the market. However, usage of
non-prescription drugs, side effects of available gastroparesis
drugs, and stringent regulatory environment for the approval of new
drugs are expected to restrain the market during the forecast period.
Moreover, lack of awareness among people about gastroparesis and
available treatments is anticipated to hamper market growth.
The global gastroparesis treatment market can be segmented based on
drug class, type, distribution channel, and region. In terms of drug
class, the market can be categorized into prokinetic agents,
botulinum toxin injection, and antiemetic agents. The prokinetic
agents segment dominated the market in 2016, owing to effectiveness,
ease of availability, high usage, and applicability of these
medications in treating gastroparesis. Based on type, the global
gastroparesis treatment market can be classified into diabetic
gastroparesis, chronic gastroparesis, idiopathic gastroparesis, and
post-operative gastroparesis. The post-operative gastroparesis
segment is anticipated to expand at a rapid pace during the forecast
period, owing to increase in the number of surgeries such as
transplantation. In terms of distribution channel, the market can be
divided into retail pharmacies, hospital pharmacies, and others. The
hospital pharmacies segment dominated the market in 2016 and the
trend is anticipated to continue during the forecast period.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39305
Geographically, the global gastroparesis treatment market can be
segmented into five major regions: North America, Latin America,
Europe, Asia Pacific, and Middle East & Africa. North America was
the largest market in terms of revenue in 2016 and the trend is
anticipated to continue during the forecast period. Growth of the
market in the region can be attributed to rise in the number of
diabetic patients. Diabetic gastroparesis is considered one of the
major forms of gastroparesis affecting the population. Europe is
expected to be the next attractive market for gastroparesis
treatment. However, sluggish economy in the region is likely to
hamper the growth of the market. The market in Asia Pacific is
anticipated to expand at a high CAGR owing to factors such as
government focus on enhancing health care facilities, rise in patient
population, and increase in product approvals.
Leading players operating in the global gastroparesis treatment
market are Boston Scientific Corporation, Cardinal Health, Inc., C.
R. Bard, Inc., Abbott Laboratories, Medtronic, Salix Pharmaceuticals,
Inc., Janssen Global Services, LLC, Teva Pharmaceuticals,
Kimberly-Clark Corporation, Rhythm Pharmaceuticals, Inc., Alfa
Wassermann SPA, and Evoke Pharma, among others.
Request for the TOC of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=39305
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment